Human Cytomegalovirus (HCMV)-infected Astrocytoma Cells Impair the Function of HCMV-specific Cytotoxic T Cells

Jiyeon Kim1,2,3, Won Woo Lee1,2,3, Eung Soo Hwang1,4

  • 1Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.

Abstract

Insights

Human cytomegalovirus (HCMV) infection impairs cytotoxic T lymphocyte (CTL) activity against glioblastoma multiforme (GBM). This HCMV-induced immune suppression may allow GBM tumors to grow unchecked by the immune system.

Area of Science:

  • Immunology
  • Virology
  • Oncology

Background:

  • Human cytomegalovirus (HCMV) infection is linked to poor prognosis in glioblastoma multiforme (GBM) and may influence GBM pathogenesis.
  • Investigating HCMV's role in impairing anti-tumor immunity is crucial for understanding GBM progression.

Purpose of the Study:

  • To determine how HCMV-infected astrocytoma cells affect the activity of cytotoxic T lymphocytes (CTLs) specific to HCMV proteins.
  • To elucidate the mechanism by which HCMV influences the anti-tumor immune response in the context of GBM.

Main Methods:

  • Cultured CD8+ T lymphocytes from healthy donors to generate HCMV immediate early (IE)-1 specific CTLs.
  • Co-cultured CTLs with HCMV-infected U373MG astrocytoma cells and assessed target cell death and effector cell viability.
  • Manipulated culture conditions, including supernatant removal and cell transfer, to evaluate CTL activity.

Main Results:

  • HCMV-infected U373MG cells significantly reduced the activity of HCMV-specific CTLs, particularly at lower effector-to-target (E:T) ratios.
  • Removal of culture supernatant from infected cells partially restored CTL-mediated target cell killing.
  • Co-culture with infected cells and subsequent transfer to new targets demonstrated impaired CTL function.

Conclusions:

  • HCMV infection in astrocytoma cells actively suppresses the function of HCMV-specific CTLs.
  • This immune suppression by HCMV may contribute to uncontrolled glioblastoma growth by evading T cell-mediated immunity.